<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01761422</url>
  </required_header>
  <id_info>
    <org_study_id>2012H0132</org_study_id>
    <nct_id>NCT01761422</nct_id>
  </id_info>
  <brief_title>Myocardial Inflammation in Systemic Lupus Erythematosus</brief_title>
  <official_title>Myocardial Inflammation in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stacy Ardoin MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to assess for myocardial edema on cardiac MRI during SLE flare to assess for&#xD;
      myocardial inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The over-arching goal of this work is to further the understanding of myocardial damage in&#xD;
      systemic lupus erythematosus (SLE) using state of the art CV imaging to investigate a novel&#xD;
      potential mechanism of CV injury in SLE, subclinical myocardial inflammation.&#xD;
&#xD;
      Aim 1: Investigate an alternative pathway for CV morbidity in SLE by measuring myocardial&#xD;
      edema at time of moderate to severe flare and compare values to post-flare studies and&#xD;
      historical healthy controls.&#xD;
&#xD;
      Hypothesis 1: Myocardial edema, measured quantitatively with T2 CMR mapping during moderate&#xD;
      to severe SLE flare will be significantly increased compared to 1) historical controls and 2)&#xD;
      in SLE patients after resolution of flare.&#xD;
&#xD;
      Aim 2: Perform exploratory analyses investigating relationships between myocardial edema on&#xD;
      CMR and markers of SLE disease activity and CV risk factors.&#xD;
&#xD;
      Hypothesis 2: Markers of disease activity including inflammatory makers (ESR and high&#xD;
      sensitivity c-reactive protein), complement and autoantibody levels will predict the presence&#xD;
      of T2 CMR detected myocardial edema during flare.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 1, 2012</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T2 edema on Cardiac MRI</measure>
    <time_frame>3 months</time_frame>
    <description>Compare T2 edema at flare and 3 months later</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>SLE</condition>
  <arm_group>
    <arm_group_label>SLE active flare</arm_group_label>
    <description>Patients who are having an active flare of their lupus confirmed by labs</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults ages 18 years and older who are diagnosed with SLE&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Diagnosis of SLE by American College of Rheumatology Classification Criteria [21]&#xD;
&#xD;
               -  Active SLE Flare defined by Systemic Lupus Erythematosus Disease Activity Index&#xD;
                  (SLEDAI)[22] &gt; 6 or British Isles Lupus Assessment Group (BILAG) Index A or&#xD;
                  B.[23]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Allergy to gadolinium&#xD;
&#xD;
          -  Severe claustrophobia&#xD;
&#xD;
          -  Renal replacement therapy or glomerular filtration rate (GFR) &lt; 30 mL/min/1.75m²&#xD;
&#xD;
          -  Medically unstable for transportation to Ross MRI scanner. Stability will be defined&#xD;
             as: not on mechanical ventilation, HR &lt; 120 BPM, MAP &gt; 65 mmHg. The treating&#xD;
             providers' input on the patient's stability will also be considered in addition to&#xD;
             these criteria&#xD;
&#xD;
          -  Weight &gt; 500 pounds&#xD;
&#xD;
          -  MR incompatible implanted devices such as neurostimulator pacemakers and implantable&#xD;
             defibrillators, presence of intracranial metal or any metal not compatible with CMR&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacy Ardoin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OSUMC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda S Kibler, BS</last_name>
      <phone>614-366-4982</phone>
      <email>amanda.kibler@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Stacy Ardoin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Stacy Ardoin MD</investigator_full_name>
    <investigator_title>Assistant Professor-Clinical</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

